The team’s findings suggest that antibodies that block CD24 and Siglec10 interactions can enhance macrophages’ effectiveness in killing tumor cells in refractory ovarian cancer, which is common in women, and triple-negative breast cancer, which is difficult to immunotherapy. This evidence concerns the gene CD24 and triple-negative breast carcinoma.